drugset / Trial / NCT07333287

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.

NCT07333287

Phase 2 Not yet recruiting 38 enrolled Shandong Provincial Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy of arterial infusion chemotherapy and embolization combined with iparplidutol-volerilis (QL1706) as first-line treatment for pancreatic cancer liver metastases based on progression-free survival (PFS).

Timeline

Start
2026-02-01
Primary completion
2027-02-28
Completion
2028-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2
Subject Iparomlimab Monoclonal antibody
Subject Paclitaxel Small molecule 125 mg/m2
Subject Rivoceranib Small molecule 250 mg
Subject Tuvonralimab Monoclonal antibody